EW - Edwards Lifesciences Faces European Scrutiny Over Patent Policies Copycat Devices | Benzinga
U.S. medical devices manufacturer Edwards Lifesciences Corp (NYSE: EW) is reportedly under the scrutiny of EU antitrust regulators for its patent practices and policies aimed at thwarting copycat devices that prompted a series of dawn raids by EU authorities last month.
The increased vigilance on both sides of the Atlantic reflects a broader effort to ensure that the pharmaceutical industry remains competitive for smaller, innovative companies and that drug and product prices stay affordable.
The primary concern of EU regulators centers on Edwards ...